Moderna Vaccine Safe for People with Comorbidities, Says BPOM
Translator
Editor
2 July 2021 14:01 WIB
TEMPO.CO, Jakarta - Food and Drug Monitoring Agency (BPOM) Head Penny Lukito in a press conference on Friday announced the safe use of US-made COVID-19 vaccine Moderna for people with comorbidities.
She explained the latest third phase clinical trial on the vaccine showed it was safe to be injected into people suffering from chronic lung disease, heart disease, severe obesity, diabetes, liver disease, and HIV.
“So it [Moderna] can be given to the population with comorbidities based on phase III clinical trial,” said Penny Lukito on Friday, July 2.
As reported earlier, the Moderna vaccine has become the first vaccine with an mRNA platform that was granted an emergency use authorization (EUA) by BPOM that entered Indonesia through the COVAX scheme.
Based on the results of phase III clinical trials, the vaccine efficacy showed 94.1 percent in the 18-65 years old age group and 86.4 percent in people aged 65 and over.
The study, which was conducted by BPOM and ITAGI, found Moderna’s safety was generally tolerable in both local reactions and systemic reactions in the form of sore, fatigue, headache, and joint muscle pain. “These emerged generally after the second injection,” said Penny Lukito.
Read: BPOM Issues Emergency Use Authorization for Moderna Vaccine
FRISKI RIANA